This paid-for advertorial by Taconic Biosciences appeared in DDW Volume 22, Issue 1 – Winter 2020/21 In the following article, Dr. Caroline Horizny from Taconic Biosciences discusses the intellectual property landscape of CRISPR/Cas9-generated mouse models. The growing complexity of preclinical research for drug development has yielded an increase in the number of genetically engineered models […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!